High-dose Antioxidants for Central Serous Chorioretinopathy

Status Completed

Clinical Trial Summary

Central serous chorioretinopathy (CSC) is the serous neurosensory detachment that usually involves the macular area. It is common in patients between 30-50 years old and effects male more often than female with the ratio of 5-10. The common risk factors are psychologic stress, type A personality, systemic steroid use, hypertension and pregnancy. The treatment is usually observation especially in the first three-months. The laser or photodynamic therapy should be considered when the condition does not improve after that time. Nevertheless, the pathogenesis of CSC is still not well understood but the study from indocyanine green angiography showed the choroidal vascular hyperpermeability and abnormal leakage. The causes of this abnormality are supposed to be from nitric oxide, prostaglandins or even free oxidative radicals. From this hypothesis, the oxidative process might be involved in the pathogenesis of the disease especially in the early stage. This study is to determine the effect of antioxidants drugs in the acute stage of CSC and to determine whether they can improve the outcomes of the disease.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Central Serous Chorioretinopathy

Clinical Trial Details

NCT number	NCT00963131
Study type	Interventional
Source	Prince of Songkla University
Contact
Status	Completed
Phase	Phase 2
Start date	December 2004
Completion date	June 2009

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03497000` - Effects of OCTA-guided PDT in Acute CSC	N/A
Recruiting	`NCT03692169` - The Changes of Retinal Capillaries After Half-dose PDT Measured by OCTA in Eyes With CSC
Not yet recruiting	`NCT02215330` - A Study of the Beneficial Effects of Eplerenone on Central Serous Chorioretinopathy	Phase 2/Phase 3
Completed	`NCT01990677` - Eplerenone for the Treatment of Central Serous Chorioretinopathy	N/A
Completed	`NCT01971190` - Efficacy and Safety of Intravitreal Aflibercept Injection for Subacute Central Serous Chorioretinopathy	Phase 2
Active, not recruiting	`NCT01710332` - The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy	Phase 2
Active, not recruiting	`NCT00403884` - Selective RPE Laser Treatment (SRT) for Various Macular Diseases	N/A
Recruiting	`NCT05570591` - Subthreshold Nanosecond Laser for Non-resolving Central Serous Chorioretinopathy	N/A
Recruiting	`NCT05589974` - Choroidal Blood Flow in Acute and Chronic Central Serous Chorioretinopathy
Completed	`NCT05104138` - Eplerenone Versus PDT: Comparative Study by OCTA
Terminated	`NCT01982383` - Study on the Use of Micropulse Laser to Treat Central Serous Chorioretinopathy	N/A
Completed	`NCT01880788` - Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD	N/A
Completed	`NCT01327170` - Micropulse Diode Laser Treatment for Chronic Central Serous Chorioretinopathy	N/A
Completed	`NCT01019668` - Central Serous Chorioretinopathy Treated by Modified Photodynamic Therapy	N/A
Recruiting	`NCT06346405` - Central Serous Chorioretinopathy and Micropulse Laser Treatment
Recruiting	`NCT02141308` - OCT in Rare Chorioretinal Diseases
Completed	`NCT01822561` - Eplerenone for Central Serous Chorioretinopathy	Phase 2
Completed	`NCT00802906` - Bevacizumab Versus Micropulse in Central Serous Chorioretinopathy (CSC)	N/A
Withdrawn	`NCT05679180` - Navigated Microsecond Laser for Chronic Central Serous Chorioretinopathy: MICROPULSE	N/A
Completed	`NCT05686421` - Comfortable and Stabilizing Chin & Forehead Rest Attachment for Slit Lamp Configurations	N/A